|Day Low/High||137.45 / 138.97|
|52 Wk Low/High||118.62 / 148.32|
The U.S. healthcare company has owned 19.9% of Ci:z since July 2016.
Acquisition is Expected to Expand J&J's Consumer Portfolio of Science-based Dermocosmetic Beauty Products
Panic is not an investment strategy, says Jim Cramer. But when everyone else is panicking, that's when you need to buy.
Stocks post sharp gains on Tuesday, getting a boost from better-than-expected earnings from investment banks Morgan Stanley and Goldman Sachs.
We are using the broader market's strength to cut our position in EMR and increase our optionality.
Pharmaceutical showed it can deliver on its above-market growth expectations, and the consumer side came in ahead of consensus.
This is what the market looks like when the Fed says nothing and the president isn't ranting about something.
Jim discusses today's market, how to treat an oversold rally, his conference last Saturday, and many stocks.
This is a battleground stock that has made big moves in both directions on earnings in the past.
Johnson & Johnson posts solid third-quarter earnings Tuesday, and boosts its full-year profit guidance.
Global stocks edged cautiously higher Tuesday, while U.S. earnings helped equity futures rise firmly into positive territory, even as investors continue to eye developments in Saudi Arabia linked to the disappearance of prominent journalist Jamal Khashoggi and fret over further signals of a trade war-related slowdown in China.
Adobe released new guidance for the rest of this year and 2019. With 20% growth in the cards, this name is a buy.
U.S. stock futures rise on Tuesday and global stocks edge mostly higher even as investors continue to eye developments in Saudi Arabia linked to the disappearance of journalist Jamal Khashoggi; Netflix, Goldman Sachs and IBM report earnings on Tuesday; Microsoft co-founder Paul Allen dies; Google's CEO defends plans for a censored search engine in China.
2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017
UnitedHealth Group, Johnson and Johnson, Goldman Sachs, Abbott Laboratories, Danaher and Textron are just some of the companies reporting earnings this week.
Jim provides his market outlook, shares his view on the financials and the aerospace/defense industry and explains some of our selling disciplines.
A look at some of the major companies in the S&P 500 slated to report financial results in the early part of next week.
This earnings season could be full of surprises. Jim Cramer has your game plan for next week.
Selling pressure appears to have abated for now as we have reached earnings season.
We are putting a small amount of capital to work by scooping up more shares of JNJ.
Be patient and let the market come in a little bit if you haven't bought yet.
Now that JNJ has fallen firmly below our basis, we are pouncing on this opportunity to scale deeper into this position.
The volatility may continue, but we'll be back Thursday putting our cash to work.
Let's review the portfolio and where we see opportunities in the market.
We are picking at a small amount of PANW as we look to reallocate the cash we raised through our exit of NUE.
The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.